China NT Pharma Group Co., Ltd. (1011) AI Stock Analysis

• Market Cap: HK$485.46M
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 674,246,030
• 10 Day Avg. Volume: 1,250,790
• 30 Day Avg. Volume: 1,683,352
• PEG Ratio: -0.07
• Price to Book (P/B): -0.17
• Price to Sales (P/S): 1.76
• P/FCF Ratio: -7.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: HK$0.50 ▼(-33.33% Downside)

The overall stock score is primarily driven by significant financial challenges, including declining revenues, persistent losses, and high leverage, leading to insolvency risks. Technical analysis indicates bearish momentum, with the stock being oversold, but lacking immediate positive catalysts. Valuation metrics are unattractive due to negative earnings and no dividend yield.

China NT Pharma Group Co., Ltd. Business Overview & Revenue Model

Company Description

China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical products in the People's Republic of China and internationally. It manufactures, sells, and trades in prescription medicines for the tumor and blood system diseases, digestive system diseases, central nervous system diseases, diseases of respiratory system, and other therapeutic fields; and produces and sells NT branded products and generic drugs. The company also provides marketing and promotion services to suppliers, and logistics and consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Suzhou, the People's Republic of China.

How the Company Makes Money

China NT Pharma Group Co., Ltd. generates revenue through multiple streams, primarily by selling its pharmaceutical products to hospitals, pharmacies, and healthcare providers across China and other markets. The company earns income from prescription medications, which are often sold in bulk to healthcare institutions, as well as from over-the-counter products that cater directly to consumers. Additionally, NT Pharma may engage in partnerships with other pharmaceutical firms for co-development and licensing agreements, which can provide significant revenue through shared sales and royalties. The company's focus on research and development also positions it to capitalize on new drug approvals and market expansions, further contributing to its earnings.

China NT Pharma Group Co., Ltd. Financial Statement Overview

Summary

The company faces significant financial challenges, including declining revenues, persistent losses, high leverage, and insolvency risks. Operational inefficiencies and liquidity issues further exacerbate the financial instability, resulting in a low score.

Income Statement

The company's income statement reflects significant revenue volatility and sustained negative net income over the past years, with a particularly sharp decline in revenue in 2023. The gross profit margin has decreased over time, and the company has struggled to achieve positive EBIT, indicating operational inefficiencies. These factors contribute to a low score.

Balance Sheet

The balance sheet shows a concerning financial structure, with negative stockholders' equity indicating insolvency risk. The debt-to-equity ratio cannot be calculated due to negative equity, but the high level of debt relative to assets suggests significant leverage. These elements indicate financial instability, contributing to a low score.

Cash Flow

The cash flow statement reveals erratic cash flow from operations, with a significant decline in free cash flow in 2024. The absence of positive free cash flow growth and the inability to cover net income with operating cash flow highlight liquidity challenges. These factors contribute to a low score.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.66M	37.96M	7.37M	207.09M	226.70M	221.73M
Gross Profit	9.57M	5.26M	7.37M	125.29M	145.46M	134.90M
EBITDA	-7.35M	-8.65M	1.33M	10.39M	-17.78M	-52.76M
Net Income	-70.92M	-53.36M	-143.59M	-66.41M	-149.54M	-357.60M
Balance Sheet
Total Assets	344.41M	334.07M	329.12M	1.01B	955.36M	1.30B
Cash, Cash Equivalents and Short-Term Investments	4.63M	9.62M	1.52M	5.93M	9.44M	7.69M
Total Debt	316.72M	375.95M	344.94M	826.45M	832.11M	851.46M
Total Liabilities	621.29M	733.18M	668.69M	1.25B	1.17B	1.27B
Stockholders Equity	-276.88M	-399.11M	-339.56M	-241.66M	-211.38M	16.28M
Cash Flow
Free Cash Flow	-22.61M	-9.24M	37.58M	31.72M	-135.42M	2.36M
Operating Cash Flow	-22.56M	-9.07M	50.48M	36.21M	-134.78M	26.20M
Investing Cash Flow	-55.00K	-189.00K	-22.14M	4.53M	257.81M	595.60M
Financing Cash Flow	23.02M	12.65M	-28.97M	-46.68M	-124.80M	-624.25M

China NT Pharma Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1011, the sentiment is Neutral. The current price of 0.75 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.95, and above the 200-day MA of 0.55, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 39.91 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1011.

China NT Pharma Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0897	55 Neutral	HK$489.42M	69.05	0.55%	6.90%	-4.92%	―
8329	54 Neutral	HK$246.67M	37.69	0.72%	3.65%	-5.98%	-81.25%
8622	53 Neutral	HK$260.25M	―	-8.71%	―	2.54%	33.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1652	49 Neutral	HK$588.18M	―	-40.38%	―	-43.46%	-96.48%
1011	39 Underperform	HK$485.46M	-2.86	―	―	―	―

China NT Pharma Group Co., Ltd. Corporate Events

China NT Pharma Announces Key Resignation

China NT Pharma Group Company Limited has announced the resignation of Mr. Cheng Cheung King from his roles as company secretary, authorised representative, and agent for acceptance of service of process and notices in Hong Kong, effective October 17, 2025. The company is actively seeking a suitable replacement for these positions and has expressed gratitude for Mr. Cheng’s contributions during his tenure.

The most recent analyst rating on (HK:1011) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.

China NT Pharma Group Shifts Focus to Smart Health Ecosystem Amid Financial Restructuring

China NT Pharma Group Co., Ltd. has announced strategic measures to enhance its business operations and financial stability. The company is focusing on developing a smart health ecosystem in the bone health sector, including testing, treatment, and rehabilitation services, which are expected to become core revenue streams. Additionally, the company has secured agreements with debtors to extend loan terms and has received financial support commitments from major shareholders to aid in its strategic transformation.

The most recent analyst rating on (HK:1011) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.

China NT Pharma Assists in Investigation, Trading Resumes

China NT Pharma Group Co., Ltd. announced that it is assisting Hong Kong Government Authorities in an investigation related to a contract with an independent third party. The company clarified that this investigation does not affect its daily operations. Following the announcement, trading of the company’s shares, which was temporarily halted, is set to resume. This development highlights the company’s transparency and commitment to regulatory compliance, ensuring minimal disruption to its stakeholders.

The most recent analyst rating on (HK:1011) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.

China NT Pharma Group Announces Trading Halt Pending Inside Information

China NT Pharma Group Co., Ltd. has announced a trading halt on its shares on the Hong Kong Stock Exchange as of August 19, 2025. This suspension is pending the release of an announcement containing inside information, which could have significant implications for the company’s operations and its stakeholders.

The most recent analyst rating on (HK:1011) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.

China NT Pharma Group Announces Change of Headquarters Address

China NT Pharma Group Co., Ltd. has announced a change in the address of its principal place of business and headquarters in Hong Kong, effective from August 18, 2025. This move could potentially impact the company’s operational logistics and stakeholder interactions, reflecting a strategic decision to optimize its business operations in the region.

China NT Pharma Reports Decline in Revenue and Comprehensive Loss for H1 2025

China NT Pharma Group Co., Ltd. reported its unaudited interim results for the first half of 2025, showing a significant decrease in revenue from RMB 31,297,000 in 2024 to RMB 11,995,000 in 2025. Despite an increase in gross profit, the company faced a comprehensive loss due to higher finance costs and changes in the fair value of financial assets, impacting its overall financial performance and market positioning.